Schrödinger
Logotype for Schrödinger Inc

Schrödinger (SDGR) investor relations material

Schrödinger UBS Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Schrödinger Inc
UBS Global Healthcare Conference summary10 Nov, 2026

Platform and strategy

  • Molecular-discovery platform serves life sciences and a growing materials-science market; software licensing is the primary monetization model, alongside early-stage therapeutics, collaborations and NewCos.

  • Product development extends beyond small-molecule discovery into formulations and biologics, with continued platform advances and AI capabilities.

  • Physics-based simulation generates data to supplement limited experimental data for AI models; internal GPU capacity supports 30,000–40,000 accurate binding-affinity calculations daily for internal programs.

  • Accuracy, 30 years of development, more than $1 billion invested in the platform, and feedback from a 200-person therapeutics team were cited as competitive advantages.

Bunsen and AI adoption

  • Bunsen, an AI agent for running discovery workflows, had internal working versions more than a year ago; scientists validated it by Q4 last year, and it is currently in beta.

  • Bunsen aims to expand calculation throughput and make workflows more accessible; it can guide users, flag potential errors and support less experienced scientists, while still requiring expert oversight.

  • A typical pharma workflow could screen far more candidate molecules before selecting a smaller set for synthesis, potentially improving success probability and speeding discovery decisions.

  • Bunsen sessions can scale a computational chemist’s work across multiple concurrent tasks; results and experimental data can feed into LiveDesign to inform molecule selection.

  • Materials-science adoption is an opportunity: Bunsen could help individual users follow best practices and shorten service-led onboarding into software sales.

Software model and growth

  • Licensing is based on software instances and calculation throughput, not user seats; greater Bunsen usage is expected to drive demand for more licenses.

  • ACV is expected to increase 12%–17% this year from $198 million; growth spans top-20 pharma, other life-science and materials customers, new products and new customers.

  • Large pharma represents roughly half of commercial business; better biotech funding conditions also supported growth.

  • Bunsen has contributed to license growth while in beta; customers are evaluating it and completing security reviews, with further license-package uptake expected as adoption develops.

  • Predictive Tox had profiled 80 off-targets; further profiling is needed to increase customer utility, while Bunsen and other products continue to evolve.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Schrödinger earnings date

Logotype for Schrödinger Inc
Q4 202624 Feb, 2027
Schrödinger
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Schrödinger earnings date

Logotype for Schrödinger Inc
Q4 202624 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The Company's solutions enable life science researchers to identify likeliest candidates from compound libraries and screen them against biological targets in the systems biology environment. Schrödinger Inc. was founded in 1990 and is based in New York.